At the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston from February 27 through March 2, findings were presented from an international study conducted by researchers and colleagues of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Allergy and Infectious Diseases (NIAID), which are both components of the National Institutes of Health (NIH).
The optimal approach to reducing mother to baby transmission of HIV is for the mother to be on antiretroviral therapy during the pregnancy. Unfortunately, there are times when treatment during the pregnancy is not possible or the mother may not be diagnosed with HIV until she is in labor. In these cases, the infants are typically treated soon after birth with zidovudine (Retrovir®), to prevent the infants from becoming infected with HIV.
To read the complete article go to www.michrx.com
